MedTrace Logo

A Study to Assess Patient-Reported Wellbeing Using Tildrakizumab in a Live Setting

NCT06488170 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 42

Last updated 2025-06-24

No results posted yet for this study

Summary

The main purpose of this study to investigate the relationship between clinical symptoms and quality of life (QoL) in participants who receive Tildrakizumab in the frame of clinical routine for the treatment of moderate to severe plaque psoriasis in accordance with the summary of product characteristics (SmPC).

Conditions

Interventions

DRUG

Tildrakizumab

As provided in real world clinical practice.

Sponsors & Collaborators

  • Almirall, S.A.

    lead INDUSTRY

Principal Investigators

  • Study Director · Almirall, S.A.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-04-04
Primary Completion
2026-01-31
Completion
2026-01-31

Countries

  • Czechia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06488170 on ClinicalTrials.gov